Keywords: acneiform rash; cutaneous side effects; epidermal growth factor receptor inhibitor; erlotinib; Japanese patients; non-small cell lung cancer; prevention; skin toxicities; ADL; activities of daily living; AEs; adverse events; BSA; body surface area; CI; co